APPROACHES OF PROVIDING WITH MEDICINES OF PATIENTS WITH PSORIASIS

Carlo V.V., Kotvitskaya A.A., Volkova A.V.
The National University of Pharmacy, Kharkov, Ukraine
socpharm@ukr.net

Numerous researches, which are devoted to a problem of treatment of psoriasis, do not define the perfect scheme of treatment of pathology, even considering a variety of medicinal preparations that are present in the pharmaceutical market. First of all this fact is explained by set of factors which influence disease emergence, and also problems in system of rendering the medical and pharmaceutical care the patient and lack of the coordinated system of normative and legal regulation of providing patients with medicinal preparations.

Definition of the main approaches to provision of medicines of patients by a psoriasis taking into account ground levels of rendering the medical and pharmaceutical care to the population became the purpose of our research. At research, methods of the comparative, logical and marketing analysis were used.

According to the marketing analysis of the range of medicinal preparations carried out by us which are recommended for complex treatment of a psoriasis, it is established that the range is characterized as rather wide and is presented by preparations of different producers and release forms. However preparations of the previous generations prevail among preparations of a domestic production.

By results of the analysis of regulating lists of medicinal preparations which regulate rendering the medical and pharmaceutical care by a sick psoriasis, it is established that in the main of them, in particular in the treatment Protocol, preparations under concrete trade names are registered instead of the indication of group of medicinal preparations of complex therapy. According to the analysis of the V release of the state form of medicinal preparations, preparations with the proved effectiveness and safety for treatment of psoriasis antimetabolites, immunosuppressant, corticosteroids and the combined dermatologic preparations the majority from which are not specified in the treatment Protocol are defined.

Considering the list of unresolved questions stated above at all levels rendering the medical and pharmaceutical care, we offered model of-level formation of approaches to optimization of providing patients by a psoriasis taking into account ground levels of rendering the medical and pharmaceutical care to the population, in particular state, regional and level of the consumer.

Thus, the main approaches to optimization of provision of medicines of patients by psoriasis consist in exercise of a complex of actions at each level of regulation and are characterized by legible definition of existing problems and a definition of concrete ways of their overcoming.